Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. files reports and updates with the U.S. Securities and Exchange Commission (SEC) as a foreign private issuer with Class A ordinary shares listed on Nasdaq under APLM and public warrants under APLMW. These filings, which include Form 20-F annual reports and multiple Form 6-K current reports, provide detailed insight into the company’s clinical-stage oncology business, financial condition, capital structure and governance. On this page, you can review Apollomics’ SEC filings alongside AI-generated summaries that help explain key points in accessible language.
What Apollomics reports in its filings
Filings describe Apollomics as a clinical-stage biopharmaceutical or biotechnology company focused on oncology therapies, with a lead program in vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with MET alterations. The company’s reports outline its broader pipeline, including APL-122 and APL-102, and discuss program decisions such as the winding down of the uproleselan (APL-106) program after a Phase 3 bridging trial in China did not show favorable benefit.
Financial statements included in these filings detail research and development expenses, administrative expenses, impairment of intangible assets, net losses and equity or deficit positions over multiple periods. Liquidity discussions highlight Apollomics’ dependence on collaboration payments and financing transactions, including PIPE financings and upfront fees under its LaunXP agreement, and describe risks if expected payments are delayed or not received.
Governance, capital structure and warrants
Form 6-K reports document changes in the board of directors and executive management, the composition of board committees, and the appointment and resignation of directors. They also describe corporate actions such as the 1-for-100 reverse share split of Class A ordinary shares, adjustments to warrant terms and exercise prices, and Nasdaq listing compliance developments. For holders or analysts of APLMW warrants, these filings explain how the reverse split affected the number of shares issuable upon exercise and the revised exercise price.
Using AI summaries for faster review
Because SEC filings can be lengthy and technical, this page pairs Apollomics’ original documents with AI-powered summaries that highlight key disclosures, such as clinical program status, material agreements, PIPE subscription terms, liquidity risks and changes in control or governance. You can quickly identify items related to oncology trial outcomes, collaboration disputes, reverse share splits, and the company’s assessment of its ability to continue as a going concern, then drill down into the full text of 20-F, 6-K and related exhibits for deeper analysis.
Apollomics Inc. entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO, Hung-Wen (Howard) Chen, providing short-term bridge financing. The Note carries a 0% interest rate and is intended to supply working capital for clinical development programs and general corporate operations.
The principal will automatically convert into Apollomics equity upon a future equity financing that raises at least $10,000,000, at a conversion price set at 80% of the lowest per-share price paid by new investors. If no such financing occurs before the 18‑month maturity, Mr. Chen may elect to convert based on the 10‑day average closing price. As a related-party transaction, it was reviewed by the independent Audit Committee and approved by the Board, with Mr. Chen abstaining.
Apollomics Inc. director and CEO Chen Hung-Wen reported his initial holdings. He holds 20,000 restricted stock units, each representing one Class A Ordinary Share. The RSUs vested for 5,000 shares on February 9, 2026, with 5,000 more vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. He also directly holds 133,334 Class A Ordinary Shares and indirectly 763,028 shares through King Regent Management Limited, over which he has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. director Hong-Jung Chen filed an initial ownership report detailing equity and derivative holdings in the company. Chen directly holds 2,120 Class A Ordinary Shares. In addition, Chen has restricted stock units representing 2,000 Class A Ordinary Shares, with 500 units vested on February 9, 2026 and 500 more vesting on each of March 15, June 15 and September 15, 2026, subject to continued service.
Chen also holds stock options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share, which are fully vested following a 1-for-100 reverse stock split adjustment. A second option grant covers 2,028 Class A Ordinary Shares at an exercise price of $6.20 per share and will vest in full on March 31, 2026, subject to continued service. The filing further discloses warrants linked to 304 Class A Ordinary Shares, reflecting an adjusted exercise price of $1,150.00 per full share, as each warrant is exercisable for 0.01 Class A Ordinary Share at $11.50 per warrant.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. disclosed on a Schedule 13D that Hung-Wen (Howard) Chen and his wholly owned vehicle, King Regent Management Limited, together hold 896,362 Class A ordinary shares, representing 41.8% of the issuer's outstanding Class A shares (2,146,151 shares outstanding as disclosed). The holdings comprise 133,334 shares directly held by Mr. Chen and 763,028 shares held by King Regent. The filing amends a prior Schedule 13G and notes that Mr. Chen is Chairman and CEO; King Regent is a private investment holding company wholly owned by him. The transaction source is identified as PIPE subscription agreements executed on September 2, 2025, and the filing includes a joint filing agreement as an exhibit.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.